Search
Now showing items 1-3 of 3
Outcomes of patients with non-small cell lung cancer and poor performance status treated with immune checkpoint inhibitors in the real-world setting
(Springer, 2021-06)
Abstract
Background: Immune-checkpoint inhibitors (ICIs) are standard treatments for metastatic non-small cell lung cancer (NSCLC). Patients with poor performance status (PS) are underrepresented in clinical trials. We ...
Immunotherapy for Hepatocellular Carcinoma: Is Latin America Ready for Primetime?
(AASLD, 2020-09)
Potential conflict of interest: Nothing to report.
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer‐related death worldwide, and its mortality is increasing steadily.1 HCC incidence has grown in the ...
Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina
(Elsevier, 2020-09)
Abstract
Background: Nivolumab was the first anti-programmed cell death 1 drug approved in Argentina for non-small-cell lung cancer treatment in the second-line setting.
Materials and methods: The present study was a ...